Cabotegravir
- Generic Name
- Cabotegravir
- Brand Names
- Apretude, Vocabria
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17F2N3O5
- CAS Number
- 1051375-10-0
- Unique Ingredient Identifier
- HMH0132Z1Q
- Background
Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine. Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.
...
- Indication
Oral cabotegravir is indicated in combination with rilpivirine for the short-term treatment of HIV-1 in virologically suppressed adults with no history of treatment failure to assess tolerability of cabotegravir or who have missed an injected dose of cabotegravir. Intramuscular extended-release cabotegravir in combination with rilpivirine is indicated as a c...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1), Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Oral Therapies
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
- Conditions
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 128
- Registration Number
- NCT05996471
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 15
- Registration Number
- NCT03149848
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa
- Locations
- 🇿🇦
CAPRISA Vulindlela Research Clinic, Mafakatini, KwaZulu-Natal, South Africa
🇿🇦CAPRISA eThekwini Research Clinic, Durban, KwaZulu-Natal, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.